

RADIOPHARM THERANOSTICS LISTS ON THE ASX AFTER RAISING \$50M IN IPO

- Radiopharm Theranostics is focused on development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs
- Highly prospective portfolio of four distinct & clearly differentiated platform technologies
- Pipeline candidate selection based on their potential to be *First to Market* or *Best in Class* in the respective therapeutic applications
- Deep clinical pipeline of five Phase 2 trials and two Phase 1 trials ongoing, with a total of 133 patients dosed to date
- Key executives secured including former AAA/Novartis CCO Riccardo Canevari as CEO & MD, Prof David Mozley as CMO and Dr Thom Tulip as CTO
- Radiopharm raised A\$50m as part of the IPO, listing with a market capitalisation of A\$152m
- The IPO received strong support from a range of institutional, sophisticated and retail investors both locally and overseas
- Bell Potter and Baker Young were Joint Lead Managers to the IPO
- [Watch a pre-listing investor presentation by Executive Chairman Paul Hopper and Managing Director & CEO Riccardo Canevari](#)

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, commences trading on the Australian Securities Exchange (ASX) today after completing a strongly supported initial public offering (IPO) that raised A\$50m from investors.

The IPO saw Radiopharm issue 83.3 million new shares at A\$0.60 per share, giving the company a market capitalisation of A\$152m at the issue price.

The IPO was very well supported by Australian and international institutional, sophisticated and retail investors.

Within its portfolio of licensed assets, Radiopharm has five phase two clinical trials and two phase one trials underway, with 133 patients dosed across three of the four assets to date.

Radiopharmaceuticals are drugs that can either act as a diagnostic, allowing physicians to see and to measure disease within the body, or as a therapeutic where high energy particles are emitted to treat cancer and other diseases.

Radiopharm has a balanced portfolio of four distinct & highly differentiated platforms, spanning peptides, small molecules and monoclonal antibodies that address approximately 75% of the causes of death from cancer:

- NanoMabs: Phase 1 & Phase 2 trials underway for diagnostics & therapeutics in solid tumours (breast & lung cancer);
- 18F-FPIA: Phase 1 & Phase 2 trials underway for diagnostic in solid tumours (brain metastases, kidney, gliomas);
- Avβ6 Integrins: Phase 1 underway for diagnostics in solid tumours (pancreatic, head & neck cancers, & pre-clinical studies underway for therapeutic use);

- hu PSA antibody: Pre-clinical studies underway for diagnostic & therapeutic use in prostate cancer.

The asset portfolio has been secured under commercially attractive license arrangements. Each technology in the portfolio is backed by a broad and robust intellectual property portfolio, with long patent lives.

Earlier in 2021, Radiopharm raised A\$20m in seed capital from investors.

The Company is Chaired by its founder Paul Hopper, who is also Executive Chairman & founder of Imugene Ltd (ASX:IMU) and Chimeric Therapeutics (ASX:CHM), former Chairman of Viralytics (ASX:VLA, acquired by Merck in 2018 for A\$502m), and has been a Chairman, Director or CEO of more than fourteen companies in the US and Australia.

Throughout this year it has assembled a team of industry experts to lead development of the portfolio. In September 2021 it appointed CEO and Managing Director Riccardo Canevari, who joined from Novartis company Advanced Accelerator Applications (AAA), where he was Chief Commercial Officer. Mr Canevari brings more than 20 years of strategic and operational experience in biotechnology and pharma.

The company has also recruited Professor David Mozley, former Professor of Nuclear Medicine at Cornell University, as its Chief Medical Officer, and Dr Thom Tulip as Chief Technical Officer, who brings more than 25 years' experience in the development and commercialisation of radiopharmaceuticals and imaging agents.

"The radiopharmaceutical sector has been gaining momentum worldwide while delivering standout results both from a diagnostic and therapeutic perspective," Mr Hopper said.

"The sector has so much untapped potential still to play out, which makes what we're doing at Radiopharm Theranostics so exhilarating for all involved."

"We've pulled together an enviable team and highly prospective assets from leading institutions, which has been reflected in the interest received from investors, and I thank them for their support."

The use of funds from the IPO will include licensing fees, clinical trials and manufacturing costs, milestone fees and employment of company personnel.

The global radiopharmaceuticals market was estimated to be valued at US\$6.7b in 2020, a number expected to reach US\$11.5b by 2027.

Bell Potter Securities and Baker Young were Joint Lead Managers to the IPO.

Investor presentation

Earlier today, Mr Hopper and Mr Canevari recorded a pre-listing investor presentation to walk investors and shareholders through the Radiopharm Theranostics story.

It can be viewed at the following link: <https://youtu.be/9SgV7V5d1hI>

Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.

For more information:

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
W: www.radiopharmtheranostics.com

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Media

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>
Twitter – <https://twitter.com/TeamRadiopharm>
Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>